CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATION

The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations. La présente invention conce...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	JELENKO, Aljosa, HILBERT, Caroline, GRIAUD, Francois, CHELIUS, Dirk, KROENER, Frieder, ANKO, Maja, PAUL, Rajsekhar, BOADO, Lina, BICKEL, Fabian, SIGG, Juergen
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to novel pharmaceutical formulations of an antibody against human P-selectin, especially SEG101, or an antibody having at most 3 amino acid difference from crizanlizumab, and processes for the preparation thereof and uses of the formulations. La présente invention concerne de nouvelles formulations pharmaceutiques d'un anticorps contre la P-sélectine humaine, en particulier SEG101, ou un anticorps ayant au plus 3 acides aminés différents du crizanlizumab, et des procédés pour leur préparation et des utilisations des formulations.